Abstract
Coronary stent thrombosis is a serious problem in the drug-eluting stent era. Despite aggressive antiplatelet therapy during and after percutaneous coronary intervention (PCI), the incidence of sub-acute stent thrombosis remains approximately 0.5%-2%, which may represent a catastrophic clinical situation. Both procedural factors and discontinuation of antiplatelet therapy are normally associated with this event. We report on simultaneous stent thromboses of two drug-eluting stents implanted in two different vessels, which resulted in a life-threatening clinical condition. Possible contributing factors that led to synergistic thrombotic effects are discussed.
Keywords:
antiplatelet therapy; diabetes mellitus; drug-eluting stent; platelet function; stent thrombosis.
MeSH terms
-
Angioplasty, Balloon, Coronary / adverse effects*
-
Angioplasty, Balloon, Coronary / instrumentation
-
Aspirin / therapeutic use
-
Cardiovascular Agents / administration & dosage
-
Clopidogrel
-
Coronary Angiography
-
Coronary Stenosis / diagnostic imaging
-
Coronary Stenosis / etiology
-
Coronary Stenosis / therapy*
-
Coronary Thrombosis / diagnostic imaging
-
Coronary Thrombosis / etiology*
-
Coronary Thrombosis / therapy
-
Diabetes Mellitus, Type 2 / complications*
-
Drug-Eluting Stents
-
Female
-
Humans
-
Medication Adherence
-
Middle Aged
-
Myocardial Infarction / diagnostic imaging
-
Myocardial Infarction / etiology
-
Myocardial Infarction / therapy*
-
Platelet Aggregation Inhibitors / therapeutic use
-
Risk Factors
-
Sirolimus / administration & dosage
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / therapeutic use
-
Treatment Outcome
Substances
-
Cardiovascular Agents
-
Platelet Aggregation Inhibitors
-
Clopidogrel
-
Ticlopidine
-
Aspirin
-
Sirolimus